Sodium iodide is under clinical development by Faraday Pharmaceuticals and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase III drugs for Myocardial Infarction have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sodium iodide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sodium iodide overview

Sodium iodide (FDY-5301) is under development for the treatment of acute myocardial infarction undergoing percutaneous coronary intervention. The drug candidate is administered through intravenous bolus injection in the form of solution. It is an elemental reducing agent, iodide anion.

It was under development for the treatment of ICU-acquired weakness (neuromuscular disorder) and tourniquet induced sarcopenia in knee-replacement patients.

Faraday Pharmaceuticals overview

Faraday Pharmaceuticals is a biopharmaceutical company focused on the development of elemental reducing agents (ERA’s) for the treatment of critical care illnesses. The company’s lead compound FDY-5301, contains iodide formulated for intravenous administration to reduce cardiac reperfusion, radiation injury and organ transplantation. The company is funded by Arch Venture Partners, Osage University Partners, Polaris Partners, and Washington Research Foundation. Faraday Pharmaceuticals is headquartered in Seattle, Washington, the US.

For a complete picture of Sodium iodide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.